Medexus Pharmaceuticals Inc.
MEDXF
$3.50
-$0.05-1.46%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.39M | -272.00K | 381.00K | 806.00K | 2.25M |
| Total Depreciation and Amortization | 9.73M | 9.71M | 9.05M | 8.19M | 7.18M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.59M | 3.17M | 4.61M | 6.72M | 8.77M |
| Change in Net Operating Assets | 4.94M | 4.76M | 2.20M | 4.04M | 5.84M |
| Cash from Operations | 18.87M | 17.36M | 16.24M | 19.76M | 24.03M |
| Capital Expenditure | -154.00K | -204.00K | -246.00K | -276.00K | -183.00K |
| Sale of Property, Plant, and Equipment | 653.00K | 653.00K | 653.00K | 653.00K | -- |
| Cash Acquisitions | -2.90M | -4.43M | -4.40M | -3.20M | -3.28M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.00M | -7.50M | -2.54M | -5.04M | -2.54M |
| Cash from Investing | -17.40M | -11.49M | -6.54M | -7.87M | -6.00M |
| Total Debt Issued | 25.57M | 25.58M | -- | -- | -- |
| Total Debt Repaid | -41.38M | -41.61M | -23.43M | -26.43M | -14.24M |
| Issuance of Common Stock | 495.00K | 19.30M | 19.30M | 19.30M | 19.30M |
| Repurchase of Common Stock | -1.53M | -375.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.08M | -2.48M | -3.06M | -3.87M | -4.27M |
| Cash from Financing | -18.92M | 418.00K | -7.19M | -11.00M | 796.00K |
| Foreign Exchange rate Adjustments | 0.00 | 238.00K | -111.00K | -17.00K | -111.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.45M | 6.53M | 2.41M | 878.00K | 18.72M |